MEI Pharma Past Earnings Performance
Past criteria checks 0/6
MEI Pharma has been growing earnings at an average annual rate of 21.1%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 23.4% per year.
Key information
21.1%
Earnings growth rate
27.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 23.4% |
| Return on equity | -187.3% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)
Feb 17
Increases to CEO Compensation Might Be Put On Hold For Now at MEI Pharma, Inc. (NASDAQ:MEIP)
Dec 30Need To Know: Analysts Are Much More Bullish On MEI Pharma, Inc. (NASDAQ:MEIP)
Nov 19We're Hopeful That MEI Pharma (NASDAQ:MEIP) Will Use Its Cash Wisely
May 18Need To Know: The Consensus Just Cut Its MEI Pharma, Inc. (NASDAQ:MEIP) Estimates For 2022
Mar 26Newsflash: MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Have Been Trimming Their Revenue Forecasts
Feb 12MEI Pharma: Another PI3K Delta Progressing To The FDA
Feb 01Need To Know: Analysts Just Made A Substantial Cut To Their MEI Pharma, Inc. (NASDAQ:MEIP) Estimates
Dec 02We're Not Very Worried About MEI Pharma's (NASDAQ:MEIP) Cash Burn Rate
Nov 04MEI Pharma EPS misses by $0.12, misses on revenue
May 06MEI Pharma promotes Richard Ghalie to chief medical officer
Apr 30MEI Pharma shares rise 4% as Wells Fargo says voruciclib undervalued
Apr 26The Independent Non-Executive Director of MEI Pharma, Inc. (NASDAQ:MEIP), Frederick Driscoll, Just Sold 40% Of Their Holding
Feb 25New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)
Feb 11
Revenue & Expenses Breakdown
How MEI Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -47 | 20 | 0 |
| 30 Jun 24 | 65 | 18 | 23 | 0 |
| 31 Mar 24 | 67 | 26 | 29 | 0 |
| 31 Dec 23 | 73 | 20 | 31 | 0 |
| 30 Sep 23 | 105 | 41 | 31 | 0 |
| 30 Jun 23 | 49 | -32 | 32 | 1 |
| 31 Mar 23 | 59 | -38 | 28 | 23 |
| 31 Dec 22 | 63 | -31 | 30 | 45 |
| 30 Sep 22 | 42 | -54 | 30 | 66 |
| 30 Jun 22 | 41 | -54 | 31 | 86 |
| 31 Mar 22 | 37 | -47 | 31 | 80 |
| 31 Dec 21 | 35 | -64 | 29 | 76 |
| 30 Sep 21 | 36 | -60 | 26 | 76 |
| 30 Jun 21 | 35 | -41 | 24 | 69 |
| 31 Mar 21 | 52 | -53 | 22 | 61 |
| 31 Dec 20 | 45 | -31 | 20 | 52 |
| 30 Sep 20 | 33 | -43 | 19 | 38 |
| 30 Jun 20 | 28 | -47 | 17 | 34 |
| 31 Mar 20 | 5 | -24 | 16 | 34 |
| 31 Dec 19 | 5 | -38 | 16 | 34 |
| 30 Sep 19 | 6 | -5 | 15 | 35 |
| 30 Jun 19 | 5 | -17 | 15 | 32 |
| 31 Mar 19 | 4 | -39 | 13 | 29 |
| 31 Dec 18 | 4 | -28 | 12 | 23 |
| 30 Sep 18 | 2 | -46 | 11 | 17 |
| 30 Jun 18 | 2 | -40 | 10 | 17 |
| 31 Mar 18 | 2 | -25 | 9 | 15 |
| 31 Dec 17 | 6 | -20 | 9 | 13 |
| 30 Sep 17 | 22 | -2 | 8 | 12 |
| 30 Jun 17 | 23 | 3 | 9 | 7 |
| 31 Mar 17 | 23 | 1 | 9 | 9 |
| 31 Dec 16 | 18 | -4 | 8 | 11 |
| 30 Sep 16 | 1 | -21 | 8 | 12 |
| 30 Jun 16 | 0 | -21 | 8 | 13 |
| 31 Mar 16 | 0 | -21 | 8 | 13 |
| 31 Dec 15 | 0 | -24 | 8 | 17 |
| 30 Sep 15 | 0 | -28 | 8 | 20 |
| 30 Jun 15 | 0 | -33 | 9 | 24 |
| 31 Mar 15 | 0 | -36 | 9 | 26 |
| 31 Dec 14 | 0 | -34 | 9 | 25 |
| 30 Sep 14 | 0 | -31 | 9 | 23 |
| 30 Jun 14 | 0 | -27 | 8 | 19 |
| 31 Mar 14 | 0 | -22 | 7 | 15 |
Quality Earnings: MEIP is currently unprofitable.
Growing Profit Margin: MEIP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MEIP is unprofitable, but has reduced losses over the past 5 years at a rate of 21.1% per year.
Accelerating Growth: Unable to compare MEIP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MEIP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: MEIP has a negative Return on Equity (-187.33%), as it is currently unprofitable.